The capacity of cytotoxic T lymphocytes (CTL) to eliminate tumor cells is the basis for the development of important tumor immunotherapies such as immune checkpoint inhibitors (e.g., anti-CTLA-4, anti-PD1, or anti-PD-L1 mAbs) and the development of cellular therapies such as CAR T cells1,2. This evidence concerns the gene CD274 and neoplasm.